Showing 101-110 of 10264 results for "".
The Importance of Early Intervention for Psoriatic Arthritis
https://practicaldermatology.com/programs/practical-dermatology-focus-psoriasis/importance-early-intervention-psoriatic-arthritis/29076/Psoriatic arthritis continues to be one of the most common and chronic manifestations of psoriatic disease. Practical Dermatology® spoke with G. Michael Lewitt, who sits on the Medical Board of the National Psoriasis Foundation, to discuss diagnosis and treatment strategies for psoriatic arthritis.Understanding Sublative Therapy
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/understanding-sublative-therapy/19056/What is sublative? Michael H. Gold, MD explains how the technology works and how it fits in practice.What Dermatologists Ought to Know About Cyspera®
https://practicaldermatology.com/topics/general-topics/what-dermatologists-ought-to-know-about-cyspera/20103/Cyspera has become a "go-to topical product for pigment," says Michael H. Gold, MD. He describes the Cyspera Intensive System and its benefits for the management of hyperpigmentation. He discusses advancements in the Cyspera formulation that enhance outcomes.The State of Private Equity in 2024: Impact on the Practice of Dermatology
https://practicaldermatology.com/columns/practice-management/state-private-equity-2024-impact-practice-dermatology/27173/Physician Growth Partners recently published a white paper, “State of Dermatology Private Equity,” that evaluated market trends, strategies, and more. Practical Dermatology® spoke exclusively with CEO Michael Kroin about how the evolution of private equity is impacting the everyday practitioner andPipeline Watch: Sizing Up a Promising Phase III IL-17 Biologic
https://practicaldermatology.com/topics/psoriasis/pipeline-watch-sizing-up-a-promising-phase-iii-il-17-biologic/21214/Pipeline Watch is a new Q&A feature appearing periodically in Practical Dermatology® that explores the potential of therapeutic agents currently under investigation. In each edition, we will speak with investigators from manufacturing companies to gain insights about the development and investigGEP Testing in Surgical Oncology
https://practicaldermatology.com/series/updates-in-skin-cancer/gep-testing-in-surgical-oncology/35601/Surgical oncologist J. Michael Guenther, MD, discusses how to use gene expression profile (GEP) testing for managing melanoma patients.Significant FDA Approval for PDT
https://practicaldermatology.com/series/pdt-in-practice/significant-fda-approval-pdt/29102/Dr. Jonathan S. Weiss discusses the importance of a recent FDA approval involving dosing of a PDT photosensitizer for both lesion-directed and field-directed treatment of actinic keratosis.Thoughts on HIPAA
https://practicaldermatology.com/topics/practice-management/thoughts-on-hipaa/19206/Michael Sacopulos, JD discusses HIPAA compliance for aesthetic practices. (Recorded June 2013)Managing Patients with Atypical Nevi and Melanoma
https://practicaldermatology.com/topics/skin-cancer-photoprotection/managing-patients-with-atypical-nevi-and-melanoma/19982/Monitoring patients with several atypical nevi who are at high risk for melanoma is very challenging. Steven Q. Wang, MD offers tips for improving diagnostic accuracy and discusses the role of dermoscopy in detecting melanoma as well as non-melanoma skin cancers at much earlier rates.James Del Rosso, DO: Thoughts on the FDA Citizen's Petition for Acne Products with Benzoyl Peroxide (BPO)
https://practicaldermatology.com/topics/acne-rosacea/james-del-rosso-do-thoughts-fda-citizens-petition-acne-products-benzoyl-peroxide-bpo/24173/James Q. Del Rosso, DO, a dermatologist and president of The American Acne and Rosacea Society (AARS), weighs in on a recent report from Valisure which finds that benzene can form at elevated levels in products for acne that contain benzoyl peroxide (BPO). The interview was conducted by Neal Bhatia,